ArticleCNS neuroscience & therapeutics2019
Feasible stabilization of chondroitinase abc enables reduced astrogliosis in a chronic model of spinal cord injury.
Article in CNS neuroscience & therapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Sustained delivery of chABC improves functional recovery after a spine injury.BMC neuroscience · 2022Pooled it
- Pathological Roles of Astrocytes in Traumatic Brain Injury.CNS neuroscience & therapeutics · 2026Review
- A sequential multimodal framework for spinal cord regeneration.Frontiers in cellular neuroscience · 2026Article
- Chondroitinase ABC in spinal cord injury: advances in delivery strategies and therapeutic synergies.Frontiers in bioengineering and biotechnology · 2025Review
- Molecular approaches for spinal cord injury treatment.Neural regeneration research · 2023Review
- 5-Fluorouracil reduces the fibrotic scar via inhibiting matrix metalloproteinase 9 and stabilizing microtubules after spinal cord injury.CNS neuroscience & therapeutics · 2022Article
- Machine-Assisted Discovery of Chondroitinase ABC Complexes toward Sustained Neural Regeneration.Advanced healthcare materials · 2022Article
- Chondroitinase ABC/galectin-3 fusion proteins with hyaluronan-based hydrogels stabilize enzyme and provide targeted enzyme activity for neural applications.Journal of neural engineering · 2021Article
- Mimicking Extracellular Matrix via Engineered Nanostructured Biomaterials for Neural Repair.Current neuropharmacology · 2021Review
- Magnetic Field Promotes Migration of Schwann Cells with Chondroitinase ABC (ChABC)-Loaded Superparamagnetic Nanoparticles Across Astrocyte Boundary in vitro.International journal of nanomedicine · 2020Article
- Acidic Fibroblast Growth Factor in Spinal Cord Injury.Neurospine · 2019Article
- Feasible stabilization of chondroitinase abc enables reduced astrogliosis in a chronic model of spinal cord injury.CNS neuroscience & therapeutics · 2019Article
- Chondroitinase ABC Administration in Locomotion Recovery After Spinal Cord Injury: A Systematic Review and Meta-analysis.Basic and clinical neuroscienceReview
- Chondroitinase ABC Enzyme: A Potential Treatment Option for Spinal Cord Injury.International journal of applied & basic medical researchArticle
- Histopathological Effects of the Intrathecal Chondroitinase ABC Administration in Spinal Cord Injured Rats: A Systematic Review.Basic and clinical neuroscienceReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsUsually, spinal cord injury (SCI) develops into a glial scar containing extracellular matrix molecules including chondroitin sulfate proteoglycans (CSPGs). Chondroitinase ABC (ChABC), from Proteus vulgaris degrading the glycosaminoglycan (GAG) side chains of CSPGs, offers the opportunity to improve the final outcome of SCI. However, ChABC usage is limited by its thermal instability, requiring protein structure modifications, consecutive injections at the lesion site, or implantation of infusion pumps.
methodsAiming at more feasible strategy to preserve ChABC catalytic activity, we assessed various stabilizing agents in different solutions and demonstrated, via a spectrophotometric protocol, that the 2.5 mol/L Sucrose solution best stabilized ChABC as far as 14 days in vitro.
resultsChABC activity was improved in both stabilizing and diluted solutions at +37°C, that is, mimicking their usage in vivo. We also verified the safety of the proposed aqueous sucrose solution in terms of viability/cytotoxicity of mouse neural stem cells (NSCs) in both proliferating and differentiating conditions in vitro. Furthermore, we showed that a single intraspinal treatment with ChABC and sucrose reduced reactive gliosis at the injury site in chronic contusive SCI in rats and slightly enhanced their locomotor recovery.
conclusionUsage of aqueous sucrose solutions may be a feasible strategy, in combination with rehabilitation, to ameliorate ChABC-based treatments to promote the regeneration of central nervous system injuries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.